LAST MEDICALLY REVIEWED:
September 2026 — Dr. Shaileshkumar Garge
Citi Vascular Hospital, KPHB Colony, Road No. 1, Hyderabad, Telangana 500072
QUICK ANSWER
What Is Vascular Erectile Dysfunction and How Is It Treated in Hyderabad?
Vascular erectile dysfunction is ED caused by a blood flow problem — either inadequate arterial inflow into the penis (arterial insufficiency, PSV < 25 cm/s on Doppler) or inability to trap blood once an erection begins (venous leak, EDV > 5 cm/s + RI < 0.75). It is the most common organic cause of ED, accounting for 40–80% of cases. Treatment options range from oral medications and lifestyle changes to shockwave therapy, PRP, and minimally invasive endovascular procedures (pudendal artery angioplasty for arterial ED, pelvic venous embolisation for venous leak) — with penile prosthesis as the final option. Dr. Garge FRCR (UK) | Citi Vascular Centre, KPHB, Hyderabad | +91-73375 83901.
Erectile dysfunction affects an estimated 52% of men between 40 and 70 years of age to some degree — and among those with a confirmed organic rather than psychogenic cause, vascular disease is responsible in the majority of cases. Despite this, most men with vascular ED spend years cycling through medications that work partially or not at all, without ever having the underlying vascular mechanism properly diagnosed. The reason is simple: the tools that accurately classify vascular ED — pharmacological penile Doppler, CT angiography, penile venography — require a specialist who understands erectile vascular physiology and is trained in both the diagnostic and interventional aspects of this field.
At Citi Vascular Centre, KPHB Colony, Hyderabad, vascular ED assessment and treatment is provided by Dr. Shaileshkumar Garge — an Interventional Radiologist with triple international credentials (FRCR UK, Fellowship USA, EBIR Spain) — who provides the complete pathway from pharmacological penile Doppler through to internal pudendal artery angioplasty and pelvic venous embolisation. This page is the complete guide to vascular ED in Hyderabad: what it is, how it is diagnosed, and what every available treatment option offers. All consultations are strictly confidential.
Vascular ED Assessment & Treatment — Citi Vascular Centre, KPHB, Hyderabad
Strictly Confidential | Call +91-73375 83901 | WhatsApp 73375 83901 | Mon–Sat 9AM–6PM
|
Feature |
Detail |
|
Vascular cause prevalence |
~40–80% of all organic (non-psychogenic) erectile dysfunction — the single most common organic ED mechanism |
|
Two vascular types |
Arterial insufficiency (inadequate inflow) | Venous leak — veno-occlusive dysfunction (inadequate venous trapping) |
|
Gold-standard diagnosis |
Pharmacological penile Doppler ultrasound after intracavernosal PGE1 injection — PSV, EDV, RI measurements |
|
Doppler thresholds |
Arterial ED: PSV < 25 cm/s | Venous leak: EDV > 5 cm/s + RI < 0.75 at peak tumescence |
|
Treatment ladder |
Lifestyle + medical → PDE5 inhibitors → Vacuum device / ICI → Shockwave/PRP → Angioplasty/Venous embolisation → Penile prosthesis |
|
Endovascular treatments |
Arterial ED: Pudendal artery angioplasty (60–80% IIEF improvement) | Venous leak: Pelvic venous embolisation (60–80%) |
|
All consultations |
Strictly confidential | Written estimates before commitment | Insurance and 0% EMI available |
An erection is fundamentally a vascular event. Sexual arousal through the autonomic nervous system triggers relaxation of the smooth muscle in the helicine arteries and cavernous spaces of the corpus cavernosum. Relaxation allows arterial blood under systemic pressure to flood the erectile bodies rapidly. As the lacunar spaces fill, they compress the subtunical venous plexus against the rigid tunica albuginea — trapping the blood and maintaining intracavernous pressure at near-systemic arterial levels (60–100 mmHg), producing the firm erection required for penetration.
Vascular ED occurs when one or both of these mechanisms fail. If the arteries supplying the penis are narrowed by atherosclerosis or trauma, not enough blood enters — this is arterial insufficiency. If the venous occlusion mechanism is incompetent — from Peyronie's disease, cavernous smooth muscle degeneration, or structural tunica abnormalities — blood enters but escapes faster than it can be trapped — this is venous leak. Many men have both mechanisms contributing simultaneously. Identifying which mechanism is dominant — through pharmacological penile Doppler — is the essential first step before choosing treatment.
Vascular ED as a cardiovascular early warning sign: The internal pudendal artery (primary penile blood supply) is approximately 1–2mm in diameter — smaller than the coronary arteries (3–4mm). Atherosclerosis narrows smaller vessels earlier. Vascular ED may therefore precede symptomatic coronary artery disease by 2–5 years in men with cardiovascular risk factors. Any man with new-onset vascular ED who has hypertension, diabetes, smoking history, or dyslipidaemia should also be assessed cardiovascularly. Call +91-73375 83901.
|
Feature |
Arterial Insufficiency |
Venous Leak (Veno-Occlusive Dysfunction) |
|
|
Core Problem |
Inadequate blood flow INTO the penis — stenosis of internal pudendal or internal iliac artery |
Blood escapes too quickly — incompetent subtunical venous plexus or tunica albuginea damage |
|
|
Typical Symptom |
Difficulty achieving any erection — poor rigidity from the outset. Morning erections typically absent. |
Erection initiates but deflates rapidly within 60–90 seconds even with maximal stimulation. |
|
|
Doppler — PSV |
< 25 cm/s — inadequate inflow |
> 25 cm/s — inflow is adequate |
|
|
Doppler — EDV |
Normal or negative at peak |
EDV > 5 cm/s at peak — venous escape |
|
|
Doppler — RI |
May be normal once pressure is adequate |
RI < 0.75 — inadequate venous resistance |
|
|
Best Endovascular Rx |
Internal pudendal artery angioplasty |
Pelvic venous embolisation (cavernous vein + pudendal vein) |
|
|
Common Causes |
Atherosclerosis | Diabetes | Post-traumatic | Smoking |
Peyronie's disease | Post-prostatectomy | Diabetes | Idiopathic |
|
Risk Factor |
How It Causes Vascular ED |
|
Diabetes mellitus |
Dual mechanism: macrovascular atherosclerosis of pudendal arteries (arterial ED) + autonomic neuropathy reducing cavernous smooth muscle relaxation (venous leak by proxy). One of the strongest independent vascular ED risk factors. |
|
Cardiovascular disease / Hypertension |
Atherosclerosis of the internal pudendal and internal iliac arteries — the same process causing coronary disease. Hypertension accelerates endothelial dysfunction. Beta-blockers and diuretics prescribed for hypertension also independently worsen ED. |
|
Smoking |
Nicotine causes immediate vasoconstriction and chronic endothelial damage in pudendal artery territory. Smoking is one of the most modifiable risk factors for vascular ED — cessation improves erectile function independently of other treatments. |
|
Age |
Progressive cavernous smooth muscle loss (replaced by connective tissue) reduces both arterial compliance and veno-occlusive capacity. Atherosclerosis accumulates. Age is the single strongest predictor of ED prevalence — but it is not inevitable or untreatable. |
|
Peyronie's Disease |
Fibrotic plaque in the tunica albuginea prevents normal circumferential expansion and disrupts subtunical venous compression — causing structural venous leak. One of the most common identifiable causes of venous leak in men under 50. |
|
Pelvic / Perineal Trauma |
Straddle injuries, pelvic fractures, cycling injuries, or post-pelvic surgery can damage the pudendal neurovascular bundle — producing post-traumatic arterial ED. This is the strongest indication for pudendal artery angioplasty (focal stenosis in a young man). |
|
Radical Prostatectomy |
Damage to the neurovascular bundles during prostatectomy affects autonomic innervation of cavernous smooth muscle. Both arterial and venous ED mechanisms can result. Nerve-sparing technique reduces but does not eliminate this risk. |
|
Dyslipidaemia |
High LDL cholesterol accelerates atherosclerosis in pudendal artery territory. Statin therapy reduces endothelial inflammation and may have independent positive effects on erectile function. |
The symptom pattern of vascular ED provides important diagnostic clues before any investigation is performed. Understanding the difference between arterial and venous symptom patterns, and between organic and psychogenic ED, allows the treating specialist to plan the appropriate investigation from the outset.
|
Symptom / Finding |
What It Suggests |
|
Gradual onset over months to years |
Strongly suggests organic / vascular cause. Psychogenic ED tends to have abrupt or situational onset — 'fine with one partner but not another' or 'fine with masturbation but not intercourse'. |
|
Absent morning erections |
Strong indicator of organic cause. Healthy morning erections depend on the nocturnal penile tumescence mechanism — a physiological vascular and neurological reflex. Their absence indicates failure of the organic mechanism. |
|
Poor erection from onset — poor inflow |
Suggests arterial insufficiency. The man cannot achieve any meaningful rigidity regardless of the level of stimulation or context. Consistent across all situations. |
|
Good initiation that rapidly deflates |
Classic venous leak pattern. The erection begins — confirming adequate arterial inflow — but cannot be maintained because venous trapping fails. |
|
Progressive deterioration over time |
Consistent with progressive atherosclerosis or worsening cavernous smooth muscle degeneration. An important contrast to abrupt onset which suggests psychogenic, medication-induced, or post-surgical cause. |
|
Associated cardiovascular symptoms |
Leg claudication, exertional chest pain, hypertension, known diabetes or dyslipidaemia — systemic atherosclerosis affecting multiple vascular beds including pudendal. |
|
Penile curvature or pain with erection |
Peyronie's disease — the most important structural cause of venous leak in younger men. Requires specific investigation and treatment alongside the venous embolisation plan. |
A structured diagnostic approach is essential for vascular ED — because the treatment choice depends directly on the mechanism identified. The diagnostic pathway has three levels: clinical assessment, vascular physiology testing (Doppler), and anatomical imaging (angiography).
|
Investigation |
What It Shows |
|
Clinical History + IIEF Score |
Establishes the severity and pattern of ED. IIEF-5 (5-question) or full IIEF-15 (15-question) quantifies erectile function domain score. History identifies onset pattern, cardiovascular risk factors, medications affecting ED (antihypertensives, antidepressants, antiandrogens), previous trauma, and relationship context. |
|
Hormonal Profile |
Testosterone (total and free), LH, prolactin, TSH — before attributing ED to vascular cause. Hypogonadism independently impairs erectile function and reduces cavernous smooth muscle responsiveness. Must be corrected before Doppler assessment or endovascular treatment is planned. |
|
Pharmacological Penile Doppler Ultrasound |
GOLD STANDARD. After intracavernosal PGE1 injection, cavernous artery PSV, EDV, and RI are measured at 5-minute intervals. PSV < 25 cm/s = arterial insufficiency. EDV > 5 cm/s + RI < 0.75 at peak = venous leak. Normal: PSV ≥ 25 cm/s, EDV < 5 cm/s at peak, RI ≥ 0.75. Performed bilaterally. |
|
CT Pelvic Angiography (CTA) |
Performed when arterial insufficiency is confirmed on Doppler and endovascular treatment (angioplasty) is being considered. Maps the internal iliac and pudendal artery anatomy — identifying the location, length, and severity of stenosis. Plans the angioplasty approach. |
|
Pelvic Venography |
Performed when venous leak is confirmed on Doppler and embolisation is being planned. Maps the cavernous vein and internal pudendal vein drainage pathways — identifying the incompetent draining channels that will be embolised. |
|
Nocturnal Penile Tumescence (NPT) Testing |
Formal NPT testing with RigiScan device measures the number, duration, and rigidity of nocturnal erections over 2–3 nights. Preserved NPT with ED during intercourse suggests psychogenic ED. Absent NPT confirms organic mechanism. Helps when clinical history is ambiguous. |
Diagnostic accuracy note: Pharmacological penile Doppler performed by an experienced operator after adequate PGE1 dose is the essential investigation before any endovascular treatment is planned. 'Resting' penile Doppler without the intracavernosal injection is not an adequate substitute — it does not produce maximal tumescence and cannot reliably measure the Doppler parameters needed to classify vascular ED. At Citi Vascular Centre, KPHB, pharmacological Doppler with full PSV, EDV, and RI reporting is performed by Dr. Garge as part of the standard vascular ED assessment. Call +91-73375 83901.
Before any procedural treatment is considered, medical optimisation and lifestyle modification are essential. Vascular risk factor management is not merely a courtesy step — it directly improves erectile vascular physiology, enhances response to medications, and may slow progression of vascular disease. In some men, aggressive lifestyle modification alone produces meaningful improvement.
|
Intervention |
Clinical Benefit for Vascular ED |
|
Smoking cessation |
Cessation reverses much of nicotine's endothelial damage in pudendal arteries. Published studies show improvement in IIEF scores after cessation. One of the most clinically impactful modifications available. |
|
Cardiovascular exercise |
Regular aerobic exercise improves endothelial function, reduces inflammation, lowers cardiovascular risk, and independently improves erectile function. Meta-analyses show significant IIEF improvement with structured aerobic training programmes. |
|
Glycaemic control |
Tight HbA1c in diabetic men reduces the rate of cavernous smooth muscle degeneration and peripheral vascular disease progression. ED in diabetic men responds better to all treatments when HbA1c is well-controlled. |
|
Dyslipidaemia treatment — statins |
Statin therapy reduces endothelial inflammation and atherosclerosis progression. Some statins have direct positive effects on endothelial nitric oxide synthase (eNOS) — enhancing smooth muscle relaxation in cavernous tissue. |
|
Testosterone optimisation |
Hypogonadal men with confirmed low testosterone should receive testosterone replacement before or alongside PDE5 inhibitor therapy. Testosterone sensitises cavernous smooth muscle to PDE5 inhibitors and independently improves erectile function. |
|
Alcohol moderation |
Chronic heavy alcohol consumption impairs autonomic function, reduces testosterone, and causes cavernous smooth muscle dysfunction. Moderation improves erectile physiology independently of other changes. |
|
Weight loss |
Obesity is an independent risk factor for ED through testosterone reduction, endothelial dysfunction, and increased insulin resistance. IIEF improvement after meaningful weight loss (> 10% body weight) is well-documented. |
PDE5 inhibitors are the established first-line pharmacological treatment for all types of erectile dysfunction, including vascular ED. They work by inhibiting the phosphodiesterase-5 enzyme that breaks down cyclic GMP in cavernous smooth muscle — increasing and prolonging the smooth muscle relaxation response to sexual stimulation. They require sexual stimulation to work — they do not create erections independently.
|
Drug |
Duration |
Key Feature |
Notes |
|
Sildenafil |
4–6 hours |
30–60 min before |
Most studied. Affected by heavy meal. Available in multiple doses (25, 50, 100mg). Generic widely available. |
|
Tadalafil |
24–36 hours |
Not food-dependent |
'Weekend tablet.' Daily low-dose (2.5–5mg) option for spontaneity and continuous endothelial benefit. |
|
Vardenafil |
4–5 hours |
Fast onset |
Similar to sildenafil. Available as oral disintegrating tablet. |
|
Avanafil |
6 hours |
Fastest onset (15 min) |
Fewer visual side effects. Useful when faster onset is needed. |
PDE5 inhibitors are most effective when some residual arterial inflow capacity exists — they enhance the mechanism, they do not create it. Men with severely reduced PSV on Doppler (very low arterial inflow) or complete venous leak may have limited or absent response to even maximum doses. When two different PDE5 inhibitors at adequate doses have been tried without meaningful improvement, the pharmacological limit has been reached and further investigation (Doppler, CTA) is warranted before escalating to other treatments.
A vacuum erection device (VED) consists of a cylinder placed over the penis, a vacuum pump that removes air and draws blood into the corpus cavernosum by negative pressure, and a constriction ring applied at the base of the cylinder before removal to trap the blood and maintain the erection. VEDs are non-pharmacological, non-invasive, and have no systemic side effects — making them a particularly appropriate option for men with cardiovascular comorbidities who cannot take PDE5 inhibitors (nitrate interactions) or who have failed medications.
The erection produced by a VED is somewhat different from a natural erection — the penis may be cooler, the constriction ring must be removed within 30 minutes to avoid ischaemia, and the pivoting effect at the base of the penis can differ from natural rigidity. Despite this, patient satisfaction rates are reasonable, particularly for older couples who prioritise functional intercourse over the precise quality of the erection. VEDs also have an evidence base for rehabilitation after radical prostatectomy — regular use promotes oxygenation of cavernous tissue and reduces smooth muscle fibrosis.
Intracavernosal injection therapy involves self-injection of a vasoactive agent — typically alprostadil (prostaglandin E1), alone or combined with papaverine and phentolamine (bi-mix or tri-mix) — directly into the corpus cavernosum. The vasoactive agent directly relaxes cavernous smooth muscle and produces an erection within 5–15 minutes that persists for 30–60 minutes and is independent of sexual stimulation.
ICI produces an erection with a success rate of 80–90% across all types of organic ED — including cases that have failed oral PDE5 inhibitors. It works when PDE5 inhibitors do not because it bypasses the PDE5 enzyme pathway and acts directly on the cavernous smooth muscle. The main limiting factors are the requirement for self-injection (initially off-putting but quickly learned by most men), the risk of priapism if the dose is too high (erection lasting > 4 hours — a medical emergency), and pain from the injection itself. ICI is also used diagnostically as part of the pharmacological Doppler assessment.
Low-intensity shockwave therapy (LiSWT) — also called penile shockwave therapy — uses low-energy acoustic pressure waves delivered to the corpus cavernosum through a handheld probe applied to the penile shaft. The mechanical energy from the shockwaves is believed to promote angiogenesis (new blood vessel formation) and improve endothelial function in cavernous tissue — potentially restoring erectile physiology at the cellular level.
LiSWT has the strongest evidence base for mild to moderate arteriogenic ED — men with PSV on the lower side of normal or borderline (25–35 cm/s) who have not responded adequately to PDE5 inhibitors but who do not have severe enough arterial disease to require angioplasty. Published meta-analyses report meaningful improvement in IIEF scores compared to sham. The effect is thought to be sustained but not permanent — most protocols consist of 12 sessions over 6 weeks. LiSWT does not involve needles, medication, or anaesthesia, making it the least invasive active treatment option beyond lifestyle changes.
|
Feature |
Detail |
|
Who benefits most |
Mild to moderate arteriogenic ED | Borderline PSV (25–35 cm/s) | Partial PDE5 inhibitor response | Men seeking non-pharmacological treatment |
|
Evidence |
Multiple RCTs and meta-analyses — IIEF improvement vs sham at 3 and 6 months. Effect may allow some men to reduce PDE5i dose or respond who previously did not. |
|
Protocol |
Typically 6–12 sessions over 3–6 weeks | Handheld probe applied to 5 penile positions | No anaesthesia | No pain in most patients |
|
Limitation |
Results vary. Not effective for severe arterial disease (very low PSV), complete venous leak, or neurogenic ED. Not a replacement for angioplasty in severe focal arterial stenosis. |
Platelet-rich plasma (PRP) therapy for ED — sometimes called the P-Shot — involves drawing a small amount of the patient's own blood, centrifuging it to concentrate the platelet-derived growth factors, and injecting the resulting PRP into the corpus cavernosum and other penile structures. The growth factors released from platelets (PDGF, VEGF, TGF-β) are believed to promote tissue repair, angiogenesis, and cavernous smooth muscle regeneration.
The evidence base for PRP in ED is emerging but limited — most studies are small, lack rigorous placebo controls (the injection itself may have a placebo component), and use heterogeneous populations. Published meta-analyses show modest improvement in IIEF scores in some patients, particularly those with mild to moderate ED. PRP appears to be safe (using the patient's own blood eliminates immunogenicity) and is increasingly offered at specialist centres. It is most rationally considered alongside shockwave therapy rather than as a replacement for properly diagnosed and classified vascular treatment. It is not a substitute for pudendal artery angioplasty in a man with confirmed PSV < 25 cm/s and focal stenosis on CTA.
Internal pudendal artery angioplasty is the most direct interventional treatment for arterial erectile dysfunction — it opens the narrowed pudendal artery segment responsible for reduced cavernous artery inflow using a balloon catheter under fluoroscopic guidance, with or without stent placement. It is the endovascular equivalent of coronary angioplasty applied to the penile blood supply.
|
Feature |
Detail |
|
Who It Is For |
Men with PSV < 25 cm/s on pharmacological Doppler | Focal pudendal artery stenosis on CTA | Age ideally < 60 | Failed PDE5 inhibitors | No severe diffuse atherosclerosis | Post-traumatic arterial ED — strongest indication |
|
How It Works |
Fluoroscopy-guided balloon catheter opened in the stenosed pudendal artery segment → restores normal lumen diameter → improves cavernous artery PSV → better erectile function. Local anaesthesia + IV sedation. Same-day discharge. |
|
Success Rate |
60–80% IIEF improvement in appropriately selected patients (published series). Best outcomes: younger men, post-traumatic, focal stenosis. |
|
Internal Link |
For the complete step-by-step procedure guide, evidence, risks, and recovery — see: Internal Pudendal Artery Angioplasty for Erectile Dysfunction [/internal-pudendal-artery-angioplasty-erectile-dysfunction] |
Pelvic venous embolisation treats venous leak erectile dysfunction by catheter-based occlusion of the incompetent internal pudendal veins and cavernous veins that allow blood to escape the corpus cavernosum too rapidly. The procedure reduces pathological venous outflow and restores the veno-occlusive mechanism — allowing intracavernous pressure to build and be maintained.
|
Feature |
Detail |
|
Who It Is For |
EDV > 5 cm/s + RI < 0.75 on pharmacological Doppler | PSV > 25 cm/s (adequate arterial inflow) | Failed PDE5 inhibitors | Erection that initiates but cannot be maintained | No dominant Peyronie's requiring separate treatment |
|
How It Works |
Fluoroscopy-guided venous catheterisation → pelvic venography maps incompetent draining veins → coils and liquid embolic agents injected to block pathological outflow. Venous access via groin. Local anaesthesia + IV sedation. Same-day discharge. |
|
Success Rate |
60–80% IIEF improvement in appropriately selected patients (published series). Best outcomes: idiopathic venous leak, younger men without Peyronie's or prostatectomy. |
|
Internal Link |
For the complete step-by-step procedure guide, venous anatomy, embolic agents, evidence, and recovery — see: Pelvic Venous Embolisation for Venous Leak Erectile Dysfunction [/pelvic-venous-embolisation-venous-leak-erectile-dysfunction] |
Inflatable penile prosthesis implantation is the most reliable and durable treatment for ED that has not responded to all other approaches. A three-piece inflatable prosthesis consists of two cylinders implanted in the corpus cavernosum, a fluid reservoir placed beneath the rectus muscle, and a small pump placed in the scrotum. Squeezing the scrotal pump transfers fluid from the reservoir into the cylinders, producing a firm erection on demand that deflates when a release mechanism is activated.
Patient satisfaction rates exceed 90% — the highest of any ED treatment — because the device delivers reliable, on-demand erection of sufficient rigidity for penetration regardless of the underlying vascular mechanism. The key limitations are irreversibility (once a prosthesis is implanted, the natural erectile tissue is permanently altered and return to natural erection is not possible) and the risks of surgical implantation (infection, mechanical failure over 10–15 years). Penile implant is appropriately offered as the final option after medications, shockwave, PRP, and endovascular approaches have been tried and found insufficient — not as an early intervention.
The most important principle in vascular ED management is matching the treatment to the mechanism. This is only possible after pharmacological penile Doppler has classified the ED — and explains why some men have excellent PDE5i responses while others with equal ED severity get no benefit.
|
Doppler Finding |
Diagnosis |
First-Line after PDE5i Fails |
Next Step if First-Line Insufficient |
|
PSV < 25 | Normal EDV |
Arterial insufficiency |
Shockwave therapy (mild) | Pudendal angioplasty (focal stenosis) |
Penile prosthesis if all endovascular options exhausted |
|
Normal PSV | EDV > 5 + RI < 0.75 |
Venous leak |
Pelvic venous embolisation |
Penile prosthesis if embolisation insufficient |
|
PSV < 25 | EDV > 5 + RI < 0.75 |
Mixed — arterial + venous |
Treat arterial first (angioplasty). Reassess venous on Doppler after arterial treatment. |
Venous embolisation if venous leak persists after angioplasty |
|
Normal PSV + Normal EDV |
Normal vascular | Neurogenic or psychogenic |
Address neurogenic/psychological cause | PDE5 inhibitors | Shockwave |
ICI | Prosthesis if neurogenic cause cannot be treated |
Q1: What is vascular erectile dysfunction?
A: Vascular erectile dysfunction is ED caused by a blood flow problem — either arterial insufficiency (not enough blood entering the penis, PSV < 25 cm/s on pharmacological Doppler) or venous leak (blood escaping before an erection can be maintained, EDV > 5 cm/s + RI < 0.75). It accounts for 40–80% of all organic ED and can be accurately diagnosed with pharmacological penile Doppler ultrasound. Both types have specific endovascular treatment options available at Citi Vascular Centre, KPHB.
Q2: What is the best treatment for vascular erectile dysfunction?
A: There is no single best treatment — the correct treatment depends on the vascular mechanism confirmed on Doppler. PDE5 inhibitors (sildenafil, tadalafil) are first-line for all types. If they fail: shockwave therapy or pudendal artery angioplasty for arterial insufficiency; pelvic venous embolisation for venous leak. Penile prosthesis is the most reliable final option when all others have been exhausted. Matching treatment to the Doppler-confirmed mechanism produces better outcomes than empirical escalation.
Q3: How is vascular ED diagnosed in Hyderabad?
A: Pharmacological penile Doppler ultrasound is the gold-standard diagnostic test — performed at Citi Vascular Centre, KPHB, Hyderabad after intracavernosal PGE1 injection to induce an erection. PSV, EDV, and RI are measured to confirm whether the ED is arterial (PSV < 25 cm/s), venous (EDV > 5 cm/s + RI < 0.75), mixed, or vascular. CT or MR angiography is performed when endovascular treatment (angioplasty) is planned. All assessments are strictly confidential. Call +91-73375 83901.
Q4: Can erectile dysfunction be treated without surgery or implant?
A: Yes — in many cases. For mild to moderate arterial ED: PDE5 inhibitors, shockwave therapy, and lifestyle modification. For focal arterial stenosis: pudendal artery angioplasty (catheter-based, no surgery). For venous leak: pelvic venous embolisation (catheter-based, no surgery). PRP/P-Shot for selected cases. Vacuum erection devices and intracavernosal injections are effective non-surgical options. Penile implant — the surgical option — is reserved for men where all non-surgical approaches have been tried and found insufficient.
Q5: Do PDE5 inhibitors (sildenafil/Viagra, tadalafil/Cialis) work for vascular ED?
A: PDE5 inhibitors work by enhancing the cavernous smooth muscle relaxation that produces an erection — they require some residual arterial function to work effectively. For mild to moderate vascular ED with partial arterial function, they are often effective. For severe arterial insufficiency (very low PSV) or complete venous leak, their efficacy is limited — because the underlying vascular mechanism is too compromised for PDE5 inhibition to overcome. Men who have failed two adequate PDE5 inhibitor trials should undergo pharmacological Doppler to classify their mechanism before further treatment.
Q6: What is shockwave therapy for erectile dysfunction?
A: Low-intensity shockwave therapy (LiSWT) uses low-energy acoustic pressure waves delivered to the penile corpus cavernosum through a probe. The mechanical energy promotes angiogenesis and endothelial function improvement. It has the best evidence base for mild to moderate arteriogenic ED in men with borderline arterial function (PSV 25–35 cm/s) who have partial PDE5 inhibitor response. Multiple RCTs show IIEF improvement vs sham. Typically 12 sessions over 6 weeks. No needles, no medication, no anaesthesia.
Q7: What is PRP / P-Shot for erectile dysfunction?
A: PRP (platelet-rich plasma) for ED involves injecting concentrated platelets from the patient's own blood into the corpus cavernosum. Growth factors released from platelets may promote cavernous tissue repair and angiogenesis. The evidence base is emerging — most published studies show modest IIEF improvement, particularly in mild to moderate ED. PRP is safe (autologous), minimally invasive, and increasingly offered alongside shockwave therapy. It is not a substitute for properly indicated endovascular treatment in men with confirmed severe arterial stenosis or venous leak.
Q8: What is internal pudendal artery angioplasty for erectile dysfunction?
A: Internal pudendal artery angioplasty opens narrowed segments of the internal pudendal artery — the penis's primary blood supply — using a balloon catheter under fluoroscopic guidance. It directly treats the arterial cause of ED. Best candidates: men with PSV < 25 cm/s on Doppler, a focal stenosis on CT angiography, failed PDE5 inhibitors, and age ideally < 60. Post-traumatic arterial ED in young men is the strongest indication. Published series report 60–80% improvement in erectile function scores. See our dedicated page for full details.
Q9: What is pelvic venous embolisation for erectile dysfunction?
A: Pelvic venous embolisation treats venous leak ED by blocking the incompetent draining veins (cavernous veins, internal pudendal veins) that allow blood to escape the corpus cavernosum before an erection can be maintained. Embolisation reduces pathological venous outflow and restores the veno-occlusive mechanism. Best for: EDV > 5 cm/s + RI < 0.75, adequate PSV, failed PDE5 inhibitors, no dominant Peyronie's. Published series report 60–80% IIEF improvement in selected patients. See our dedicated page for full details.
Q10: Is erectile dysfunction a sign of heart disease?
A: Arterial vascular ED may be an early indicator of systemic atherosclerosis — the same disease affecting coronary arteries, though in smaller vessels that narrow earlier. The internal pudendal artery (1–2mm) obstructs before the coronary arteries (3–4mm) in many men. Published evidence suggests that ED may precede a symptomatic cardiac event by 2–5 years in men with cardiovascular risk factors. Men with new-onset vascular ED and risk factors (diabetes, hypertension, smoking, dyslipidaemia) should also be assessed for cardiovascular risk by their physician or cardiologist.
Q11: Can venous leak erectile dysfunction be cured?
A: Venous leak can be meaningfully improved — but 'cured' depends on the underlying cause and mechanism. Idiopathic venous leak in younger men treated with pelvic venous embolisation shows 60–80% IIEF improvement in published series. If the embolised veins remain occluded, the improvement can be durable. Recanalisation (re-opening of embolised veins) can occur in 15–25% of cases over years — and repeat embolisation is feasible. Venous leak from structural Peyronie's disease requires treatment of the Peyronie's alongside the venous embolisation for durable results.
Q12: Who is the best doctor for vascular erectile dysfunction in Hyderabad?
A: Dr. Shaileshkumar Garge — FRCR (UK), FNVIR (CMC Vellore), EBIR (Spain) — Director and Chief Vascular Physician at Citi Vascular Centre, KPHB Colony, Hyderabad, is one of the city's most internationally credentialled Interventional Radiologists for vascular ED diagnosis and endovascular treatment. He provides: pharmacological penile Doppler assessment; CTA and venography; pudendal artery angioplasty; pelvic venous embolisation — the complete endovascular ED pathway under one specialist. All consultations are strictly confidential. Call +91-73375 83901 or WhatsApp 73375 83901.
|
Reference |
Key Relevance |
|
Lue TF. Erectile Dysfunction. NEJM. 2000;342:1802–1813. |
Foundational review — vascular physiology of erection, Doppler parameters (PSV, EDV, RI) as diagnostic thresholds. Established the pharmacological Doppler as gold standard for vascular ED classification. |
|
Feldman HA et al. Impotence and medical comorbidities: MMAS. J Urol. 1994. |
Massachusetts Male Aging Study — established the prevalence of ED across age groups (52% of men 40–70) and the association with cardiovascular risk factors, diabetes, and smoking. |
|
Baten E et al. Endovascular treatment of erectile dysfunction. Eur Urol Focus. 2023. |
Systematic review of endovascular approaches for vascular ED — confirms 60–80% improvement with both arterial angioplasty and venous embolisation in appropriately selected patients. |
|
Clavijo RI et al. Low-intensity shockwave therapy for erectile dysfunction — systematic review. J Sex Med. 2017. |
Meta-analysis of LiSWT RCTs — confirms significant IIEF improvement vs sham in arteriogenic ED. Identifies mild to moderate arteriogenic ED as the optimal indication. |
|
EAU Guidelines on Sexual and Reproductive Health — Erectile Dysfunction. 2024. |
Current European Association of Urology evidence-based guidelines — treatment algorithm positions PDE5i as first-line, with endovascular treatments as options for vascular ED after PDE5i failure, before prosthesis. |
Citi Vascular Centre, KPHB Colony, Road No. 1, Hyderabad — complete vascular ED assessment and endovascular treatment for patients from:
Kukatpally and KPHB — 5 min | Miyapur and Bachupally — 10 min
Hitech City, Ameerpet and Madhapur — 20 min | Gachibowli, Banjara Hills — 25 min
Secunderabad and Begumpet — 25 min | Telangana & AP — outstation welcome
|
Centre |
Contact |
Appointments |
|
Citi Vascular Centre |
+91-73375 83901 |
KPHB Colony, Road No. 1, Hyderabad 500072 | Mon–Sat 9AM–6PM |
|
|
73375 83901 |
All consultations strictly confidential | Outstation welcome | 0% EMI | Insurance assisted |
Vascular erectile dysfunction — the most common form of organic ED — is caused by either arterial insufficiency (inadequate penile blood inflow from pudendal artery stenosis) or venous leak (inadequate veno-occlusion allowing blood to escape). Both types can be accurately diagnosed with pharmacological penile Doppler ultrasound and, in appropriately selected patients, treated through the full range of available options: lifestyle modification, PDE5 inhibitors, vacuum devices, intracavernosal injections, shockwave therapy, PRP, minimally invasive catheter-based endovascular procedures, and finally penile prosthesis for those where all other treatments have been exhausted.
The key principle is mechanism-specific treatment: Doppler-guided classification of the vascular type comes first, followed by the appropriate intervention for that mechanism. Men who have been told only that 'your ED does not respond to Viagra' deserve a proper investigation of why — Doppler may reveal a focal pudendal artery stenosis ideal for angioplasty, or a venous leak pattern ideal for embolisation, that transforms outcomes compared with continued empirical medication escalation. At Citi Vascular Centre, KPHB Colony, Hyderabad, Dr. Shaileshkumar Garge provides the complete vascular ED assessment and endovascular treatment pathway under one specialist — in a strictly confidential setting. Call +91-73375 83901 or WhatsApp 73375 83901.
Vascular Erectile Dysfunction — Complete Assessment & Treatment | Citi Vascular Centre, KPHB, Hyderabad
Penile Doppler | CTA / Venography | Shockwave | Angioplasty | Venous Embolisation | Strictly Confidential
Dr. Shaileshkumar Garge | FRCR (UK) | FNVIR (CMC Vellore) | EBIR (Spain) | 12+ Years | 15,000+ Procedures
Call +91-73375 83901 | WhatsApp 73375 83901 | citivascularcentre.com
KPHB Colony, Hyderabad | Mon–Sat 9AM–6PM | All Consultations Strictly Confidential
